We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+23.77%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$4.34B
AUM Growth
+$467M
Cap. Flow
-$99.7M
Cap. Flow %
-2.3%
Top 10 Hldgs %
48.91%
Holding
111
New
4
Increased
17
Reduced
21
Closed
25

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$50.7M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$47.6M
3
PTCT icon
PTC Therapeutics
PTCT
+$28.2M
4
IMCR icon
Immunocore
IMCR
+$21.7M
5
AXSM icon
Axsome Therapeutics
AXSM
+$13.2M

Top Sells

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$32.9M
2
QTRX icon
Quanterix
QTRX
+$29.5M
3
VERU icon
Veru
VERU
+$25.1M
4
GMED icon
Globus Medical
GMED
+$22.5M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
2 Financials 0.67%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
26
DELISTED
Ventyx Biosciences
VTYX
$54.2M 1.25%
1,551,778
– –
PMVP icon
27
PMV Pharmaceuticals
PMVP
$63.5M
$51.8M 1.2%
4,356,920
-38,757
-0.9% -$560K
RGNX icon
28
Regenxbio
RGNX
$708M
$48.8M 1.12%
1,845,366
– –
STOK icon
29
Stoke Therapeutics
STOK
$2.11B
$46.9M 1.08%
3,651,823
– –
CINC
30
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$45.6M 1.05%
1,389,705
– –
GMED icon
31
Globus Medical
GMED
$11.2B
$44.5M 1.03%
747,685
-373,842
-33% -$22.5M
MIST icon
32
Milestone Pharmaceuticals
MIST
$152M
$39.7M 0.91%
4,315,102
– –
GH icon
33
Guardant Health
GH
$22.6B
$39.1M 0.9%
725,887
-199,000
-22% -$10.2M
PTGX icon
34
Protagonist Therapeutics
PTGX
$9.44B
$35.2M 0.81%
4,176,837
-617,662
-13% -$5.84M
TARS icon
35
Tarsus Pharmaceuticals
TARS
$2.84B
$34.6M 0.8%
2,023,179
+9,578
+0.5% +$152K
FULC icon
36
Fulcrum Therapeutics
FULC
$297M
$32.2M 0.74%
3,985,910
+24,716
+0.6% +$177K
BCYC
37
Bicycle Therapeutics
BCYC
$292M
$29.7M 0.68%
1,276,276
– –
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$28.8M 0.66%
5,741,939
– –
GHRS icon
39
GH Research
GHRS
$2.08B
$25.2M 0.58%
2,168,957
– –
CCCC icon
40
C4 Therapeutics
CCCC
$412M
$24.7M 0.57%
2,819,472
-275,353
-9% -$2.86M
TXG icon
41
10x Genomics
TXG
$6.61B
$18.2M 0.42%
639,654
-319,827
-33% -$12.2M
TSVT
42
DELISTED
2seventy bio
TSVT
$17.9M 0.41%
1,229,508
– –
TNDM icon
43
Tandem Diabetes Care
TNDM
$1.56B
$15.4M 0.36%
322,000
-600,630
-65% -$32.9M
APYX icon
44
Apyx Medical
APYX
$171M
$15.3M 0.35%
3,398,279
– –
OM icon
45
Outset Medical
OM
$90.8M
$14.5M 0.33%
60,643
– –
CSTL icon
46
Castle Biosciences
CSTL
$979M
$13.5M 0.31%
516,995
-396,794
-43% -$11.1M
DMTK
47
DELISTED
DermTech, Inc. Common Stock
DMTK
$12.3M 0.28%
3,118,666
– –
JNCE
48
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$11.9M 0.28%
5,106,341
+747,908
+17% +$2.65M
OLK
49
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$11.9M 0.27%
981,918
-580,304
-37% -$8.89M
THRD
50
DELISTED
Third Harmonic Bio
THRD
$11.6M 0.27%
+609,687
New +$11M
1
2
3 4 5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q3 2022 Portfolio in Review

As of Q3 2022, RTW Investments held 111 positions worth $4.34B, up 12% from $3.87B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

RTW Investments's Q3 2022 filing shows 4 new, 17 increased, 21 reduced and 25 closed positions. Its largest new stake was IVERIC bio, Inc. Common Stock: 3,625,000 shares worth $65M. The largest sale was Tandem Diabetes Care, an estimated $32.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Industrials.

  • RTW Investments's largest Q3 2022 buy was IVERIC bio, Inc. Common Stock: 3,625,000 shares worth $65M.
  • RTW Investments added most to Ultragenyx Pharmaceutical in Q3 2022, an estimated $50.7M increase.
  • RTW Investments's biggest Q3 2022 reduction was Tandem Diabetes Care, cutting an estimated $32.9M.
  • RTW Investments fully exited Quanterix in Q3 2022, selling an estimated $29.5M.
  • RTW Investments's ten largest holdings make up 49% of its $4.34B portfolio in Q3 2022.
  • RTW Investments opened 4 new positions and closed 25 in Q3 2022.
  • RTW Investments's portfolio value rose 12% quarter-over-quarter to $4.34B.

Based on RTW Investments's 13F filing for Q3 2022, filed 14 Nov 2022.